Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Efficacy of etanercept in rheumatoid arthritis patients and its effects on interleukin-6 and serum tumor necrosis factor α

Suihu Li¹, Qinghua Mei¹ , Dan Qian², Xianghong Huang², Cuimiao Fan¹, Jia Quan¹

¹Department of Pharmacy, Guangdong Second Provincial General Hospital, Guangzhou 510000, PR China; ²Department of Pharmacy, Children's Hospital of Yuexiu District, Guangzhou 510000, PR China.

For correspondence:- Qinghua Mei Email: qal5uw@163.com

Accepted: 6 December 2022 Published: 31 January 2023

Citation: Li S, Mei Q, Qian D, Huang X, Fan C, Quan J. Efficacy of etanercept in rheumatoid arthritis patients and its effects on interleukin-6 and serum tumor necrosis factor α. Trop J Pharm Res 2023; 22(1):207-213 doi: 10.4314/tjpr.v22i1.28

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To study the effects of etanercept (ETA) on the clinical manifestations and serum levels of TNF-α and IL-6 in rheumatoid arthritis (RA) patients.

Methods: A retrospective analysis was performed on the medical files of 138 active RA patients admitted to Guangdong Second Provincial General Hospital, Guangzhou, China for rheumatic diseases from January 2016 to February 2019. Out of the total subjects, 58 patients were administered conventional methotrexate (MTX) as routine treatment (control group), while the remaining 80 patients (classified as study group) received subcutaneous injection of etanercept (ETA). Health Assessment Questionnaire (HAQ) score, and TNF-α and IL-6 serum concentrations of the two groups before and after treatment were assessed.

Results: Pre-treatment HAQ score was comparable in both groups (p > 0.05). However, at 3, 6, 9 and 12 weeks post-treatment, HAQ scores decreased in the two groups. The mean score was significantly lower in study group than in control group (p < 0.001). Pre-treatment serum levels of IL-6 and TNF-α in both groups were comparable. However, after treating for 3, 6, 9 and 12 weeks, serum IL-6 and TNF-α decreased significantly, with lower values in the study group than in control group (p < 0.001).

Conclusion: ETA has a higher efficacy and safety than MTX for the treatment of joint inflammation and and also achieved greater improvement of joint function. However, further clinical trials are recommended prior to wider application in clinical practice.

Keywords: Etanercept, Rheumatoid arthritis, Clinical efficacy, Interleukin-6, Serum TNF-α